Approval · Notice of Compliance 30773 · 2023

ABEVMY: Notice of Compliance 30773

Issued May 15, 2023

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 30773
Date: May 15, 2023
Company: Biosimilar Collaborations Ireland LimitedDublin, --, Ireland
Product type: Biologic
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Administrative ¿ Change in Product Ownership
Canadian reference product: AVASTIN

Products in this notice

Brand	DIN	Status today
ABEVMY	02522179	Marketed
ABEVMY	02522160	Marketed

Medicinal ingredients

BEVACIZUMAB 100 MG per 4ML
BEVACIZUMAB 400 MG per 16ML